文献速递妇科产科

美国子宫肉瘤组织学亚型的子宫切除校正发病率与生存分析(2000-2019)

Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019.
PubMed 文献 · Am J Obstet Gynecol · 2026-10-28

基于SEER 22登记库2000-2019年14,801例≥20岁显微镜确诊子宫肉瘤的回顾性人群研究,按组织学亚型、分期和种族/民族计算子宫切除校正的年龄别发病率和五年相对生存率。平滑肌肉瘤最常见(53.3%)且发病率最高(0.6/10万)、生存最差;非西班牙裔黑人各亚型发病率最高、更易远处转移且生存最低。

要点

  • 平滑肌肉瘤占53.3%,子宫切除校正发病率0.6/10万,五年相对生存42.3%。
  • 非西班牙裔黑人各组织学亚型发病率均最高,更易诊断时即为远处病变且生存最低(41.9%)。
  • 局限期各亚型相对生存62%–85%,远处转移期仅13.5%–34.7%。

核心结论

  • 子宫肉瘤各组织学亚型在发病模式和生存轨迹上差异显著,平滑肌肉瘤发病率最高且生存较ESS和腺肉瘤更差。
  • 非西班牙裔黑人各亚型发病率最高,更易为晚期病变且生存更差,需关注该人群的差异问题。

研究设计与样本

  • 回顾性人群为基础研究,纳入SEER 22登记库2000-2019年显微镜确诊、年龄≥20岁的子宫肉瘤病例,共14,801例。
  • 计算子宫切除校正的年龄别发病率(按组织学亚型、诊断分期、种族/民族),并用Ederer II法估算五年相对生存率。

主要发现

  • 平滑肌肉瘤占53.3%(n=7883),子宫内膜间质肉瘤占26.7%(n=3948),腺肉瘤占12.7%(n=1884),NOS肉瘤占5.7%(n=837),未分化肉瘤占1.7%(n=249)。
  • 子宫肉瘤发病率随年龄增至50-54岁后趋于平台,但非西班牙裔黑人持续增至65-69岁。
  • 子宫切除校正发病率:平滑肌肉瘤0.6/10万,ESS 0.3/10万,腺肉瘤0.1/10万。
  • 五年相对生存:平滑肌肉瘤42.3%(95%CI 41-43.5),ESS 70.2%(68.5-71.8),腺肉瘤78.3%(75.7-80.6)。
  • 按分期,局限期各亚型相对生存62%–85%,远处转移期13.5%–34.7%;非西班牙裔黑人总体41.9%,非西班牙裔白人55.4%。

关键数值与推荐

  • 子宫切除校正发病率:平滑肌肉瘤0.6/10万、ESS 0.3/10万、腺肉瘤0.1/10万。
  • 五年相对生存:平滑肌肉瘤42.3%(95%CI 41-43.5)、ESS 70.2%(68.5-71.8)、腺肉瘤78.3%(75.7-80.6)。
  • 局限期相对生存62%–85%,远处转移期13.5%–34.7%;非西班牙裔黑人41.9% vs 非西班牙裔白人55.4%。

临床怎么用

  • 接诊子宫肉瘤时应按组织学亚型评估预后,平滑肌肉瘤需警惕最高发病率和最差生存。
  • 对非西班牙裔黑人患者应提高警惕,关注晚期病变风险及生存差异。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uterine sarcomas are rare but aggressive mesenchymal malignancies of the uterus, characterized by diverse histotypes and poor survival. However, little is known about the epidemiology and clinical characteristics of uterine sarcoma histotypes at the population level. OBJECTIVE: To evaluate hysterectomy-corrected, age-specific incidence rates and five-year relative survival by histologic subtype, stage at diagnosis, and race/ethnicity among U.S. individuals aged ≥20 years diagnosed with uterine sarcoma in the SEER 22 registries from 2000-2019. STUDY DESIGN: This retrospective population-based study included microscopically confirmed uterine sarcoma cases registered in the SEER 22 database. Hysterectomy-corrected, age-specific incidence rates were calculated by histotype, stage at diagnosis, and race/ethnicity. Five-year relative survival was estimated using the Ederer II method in SEER*Stat software (version 9.0.42). RESULTS: A total of 14,801 individuals aged ≥20 years diagnosed with uterine sarcoma were included. Leiomyosarcoma (LMS) were most common comprising 53.3% of the total cases (n=7883), endometrial stromal sarcoma (ESS) accounted for 26.7% of cases (n=3948), Adenosarcoma for 12.7% (n=1884), sarcoma not otherwise specified (NOS) for 5.7% (n=837), and undifferentiated sarcoma for 1.7% of cases (n=249). Incidence rates of uterine sarcomas increased until ages 50-54 and plateaued thereafter other than among Non-Hispanic Black (NHB) individuals, where incidence continued to increase until ages 65-69 years. LMS demonstrated the highest hysterectomy-corrected incidence (0.6 per 100,000), followed by ESS (0.3 per 100,000) and Adenosarcoma (0.1 per 100,000). NHB individuals had the highest incidence of uterine sarcomas across all histotypes. Overall, NHB individuals were more likely to be diagnosed with distant diseases compared with other groups. Among all individuals, five-year relative survival was 42.3% (95% CI: 41-43.5) for LMS, 70.2% (68.5-71.8) for ESS, and 78.3% (75.7-80.6) for Adenosarcoma. When categorized by stage at diagnosis, relative survival for localized disease ranged from 62% to 85% in all histotypes, vs. 13.5% to 34.7% for distant metastatic disease. Survival was lowest among NHB individuals, 41.9%, versus 55.4 % in Non-Hispanic White (NHW) individuals, across all histotypes and stage at diagnosis. CONCLUSION: Uterine sarcomas exhibit pronounced heterogeneity, comprising distinct histotypes that demonstrate variable incidence patterns and survival trajectories. LMS had the highest incidence and worse survival compared with ESS and Adenosarcoma. NHB individuals had the highest incidence rates for all histotypes and were more likely to have advanced disease and worse survival compared with other groups. Future studies are required to evaluate underlying risk factors, early detection strategies, and response to therapy by histotype, with a particular focus on addressing disparities in NHB individuals.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Dave D, Arend RC, Leath CA, et al. Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019. Am J Obstet Gynecol. 2026. PMID: 42951232. doi:10.1016/j.ajog.2026.10.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。